About Us
Accelerating Development to Commercialization of Revolutionary Therapeutics.
With our fully integrated, enhanced portfolio, Pluristyx, powered by panCELLa offers the fastest path to clinic and the most optimal route to commercialization. Today, Pluristyx provides end-to-end support in early product development backed by an iPSC based portfolio while panCella offers an array of unique and effective technologies with competency in gene editing. Our vision for the future is to expand our technology and products base and deepen our operating capabilities to become the global leader in clinical-grade, genetically modified iPSCs with the lowest barrier to entry for cell therapy development.
Mission
Pluristyx, powered by panCELLa aspires to become the leading provider of cell therapy products, services, and technologies by supporting our client’s research and therapeutic product development efforts, expediting a streamlined pathway to clinic and commercialization.
Values
Quality – Deliver products and services of the highest caliber and merit
Integrity – Act with moral and ethical strength to do what is right
Leadership – Translate vision and ideas into actions and outcomes
Passionate – Perform work that will have a positive societal impact
Values
Committed - Anticipate needs and challenges and aim to exceed expectations
Innovation – Utilize scientific know-how to deliver cutting-edge services and products
Character - Conduct ourselves with highest ethical standards: we are open, honest, and transparent.
About Pluristyx
Established in 2018 as an advanced therapy tools company, Pluristyx helps companies and researchers solve manufacturing challenges in the field of drug development, regenerative medicine, and cell and gene therapy. Pluristyx has provided seamless support through CMC consulting, contract development services, and research- and clinical-grade Ready-to-Use (RTU™) and Ready-To-Differentiate (RTD®) Pluripotent Stem Cells at a commercial scale.
Effectively removing the barriers of expansion and banking from differentiation and product development, allowing early-stage companies to focus their precious resources on therapeutic application rather than manufacturing hurdles, with the goal of advancing promising laboratory discoveries to benefit the patients.
About Pluristyx
Established in 2018 as an advanced therapy tools company, Pluristyx helps companies and researchers solve manufacturing challenges in the field of drug development, regenerative medicine, and cell and gene therapy. Pluristyx has provided seamless support through CMC consulting, contract development services, and research- and clinical-grade Ready-to-Use (RTU™) and Ready-To-Differentiate (RTD®) Pluripotent Stem Cells at a commercial scale.
Effectively removing the barriers of expansion and banking from differentiation and product development, allowing early-stage companies to focus their precious resources on therapeutic application rather than manufacturing hurdles, with the goal of advancing promising laboratory discoveries to benefit the patients.
About panCELLa
Co-founded in 2015 by Dr. Andras Nagy, (PhD, stem cell biologist), and Dr. Armand Keating (MD, PhD, clinical scientist hematologist), panCELLa has created platforms that develop safe, universal, cost-effective, “off-the-shelf” therapeutic cell products for medicine. Having secured partnerships with several biotechnology partners, panCELLa enhanced its patent position and expanded its access to exclusive FailSafe® and iACT Stealth cells™.
In fall, 2022, panCELLa merged with Pluristyx, Inc streamlining access to the next generation of safe, universal, and cost-effective “off-the-shelf” iPSCs. Pluristyx powered by panCELLa’s iPSCs are generated through a proprietary mRNA-based technology. They are conveniently available in a ‘Try Before You Buy’ research evaluation model requiring low up-front licensing fees.
Packaged in Pluristyx’s high-density Ready-to-Differentiate® format, iPSCs containing panCELLa’s proprietary technologies offer customers, at any stage of product development, the ability to rapidly assess and select lines for further development and manufacturing. Since Plurisytx powered by panCELLa iPSC’s are sourced from clinical-grade material, commercial partners can readily transition from development to therapeutic manufacturing.
About panCELLa
Co-founded in 2015 by Dr. Andras Nagy, (PhD, stem cell biologist), and Dr. Armand Keating (MD, PhD, clinical scientist hematologist), panCELLa has created platforms that develop safe, universal, cost-effective, “off-the-shelf” therapeutic cell products for medicine. Having secured partnerships with several biotechnology partners, panCELLa enhanced its patent position and expanded its access to exclusive FailSafe® and iACT Stealth cells™.
In fall, 2022, panCELLa merged with Pluristyx, Inc streamlining access to the next generation of safe, universal, and cost-effective “off-the-shelf” iPSCs. Pluristyx powered by panCELLa’s iPSCs are generated through a proprietary mRNA-based technology. They are conveniently available in a ‘try-before-you-buy’ research evaluation model requiring low up-front licensing fees.
Packaged in Pluristyx’s high-density Ready-to-Differentiate® format, iPSCs containing panCELLa’s proprietary technologies offer customers, at any stage of product development, the ability to rapidly assess and select lines for further development and manufacturing. Since Plurisytx powered by panCELLa iPSC’s are sourced from clinical-grade material, commercial partners can readily transition from development to therapeutic manufacturing.